Why is Shukra Pharma. falling/rising?

As of 16-Jul, Shukra Pharmaceuticals Ltd is experiencing a price increase, currently at 21.58, reflecting a rise of 0.42 or 1.98%. The stock has shown impressive performance, gaining 61.04% over the last 14 days and outperforming its sector by 2.25% today. Additionally, it has delivered substantial returns over various periods, including a remarkable 146.07% increase over the past year. Despite a recent decline in delivery volume, the stock remains liquid enough for trading, and its ability to service debt is strong, supported by a low Debt to EBITDA ratio of 1.28 times and a healthy annual operating profit growth rate of 60.53%. However, it is important to note that the company has faced challenges, including a significant drop in net sales and profits over the past year, which may raise concerns about its valuation.
In the broader market context, Shukra Pharmaceuticals has significantly outperformed the benchmark, with a 10.27% increase over the past week compared to a decline of 1.08% in the Sensex. This trend continues with a 50.59% rise over the past month against a modest 1.02% gain in the benchmark. While the stock's performance is impressive, the lack of domestic mutual fund investment, which stands at 0%, may indicate caution among institutional investors regarding its current valuation and business prospects. Overall, the stock's recent rise can be attributed to its strong performance metrics and growth potential, despite underlying concerns about profitability and market perception.